Quantinno Capital Management LP Acquires 1,190 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Quantinno Capital Management LP boosted its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 35.4% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 4,556 shares of the biopharmaceutical company's stock after purchasing an additional 1,190 shares during the period. Quantinno Capital Management LP's holdings in Alnylam Pharmaceuticals were worth $1,072,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the company. Parkman Healthcare Partners LLC boosted its holdings in shares of Alnylam Pharmaceuticals by 51.7% in the fourth quarter. Parkman Healthcare Partners LLC now owns 38,672 shares of the biopharmaceutical company's stock worth $9,100,000 after buying an additional 13,187 shares during the last quarter. Nissay Asset Management Corp Japan ADV boosted its stake in shares of Alnylam Pharmaceuticals by 2.1% during the 4th quarter. Nissay Asset Management Corp Japan ADV now owns 15,947 shares of the biopharmaceutical company's stock worth $3,795,000 after acquiring an additional 324 shares during the last quarter. OMERS ADMINISTRATION Corp boosted its stake in shares of Alnylam Pharmaceuticals by 20.4% during the 4th quarter. OMERS ADMINISTRATION Corp now owns 5,252 shares of the biopharmaceutical company's stock worth $1,236,000 after acquiring an additional 891 shares during the last quarter. Orbimed Advisors LLC grew its position in shares of Alnylam Pharmaceuticals by 66.0% during the 4th quarter. Orbimed Advisors LLC now owns 415,600 shares of the biopharmaceutical company's stock valued at $97,795,000 after acquiring an additional 165,300 shares during the period. Finally, Integral Health Asset Management LLC increased its stake in shares of Alnylam Pharmaceuticals by 80.0% in the 4th quarter. Integral Health Asset Management LLC now owns 45,000 shares of the biopharmaceutical company's stock worth $10,589,000 after purchasing an additional 20,000 shares in the last quarter. 92.97% of the stock is currently owned by institutional investors.

Alnylam Pharmaceuticals Trading Down 0.6%

Shares of NASDAQ ALNY traded down $1.62 during trading hours on Wednesday, hitting $288.49. 369,437 shares of the company traded hands, compared to its average volume of 915,875. The company's 50 day moving average price is $259.82 and its 200 day moving average price is $254.53. Alnylam Pharmaceuticals, Inc. has a 12 month low of $146.79 and a 12 month high of $304.39. The stock has a market capitalization of $37.61 billion, a price-to-earnings ratio of -132.62 and a beta of 0.17. The company has a current ratio of 2.78, a quick ratio of 2.71 and a debt-to-equity ratio of 15.27.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The biopharmaceutical company reported ($0.44) earnings per share for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.07). The business had revenue of $594.19 million for the quarter, compared to analyst estimates of $584.32 million. The firm's revenue was up 20.2% on a year-over-year basis. During the same quarter last year, the business earned ($0.16) EPS. On average, equities research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the company. Needham & Company LLC reiterated a "buy" rating and set a $320.00 target price on shares of Alnylam Pharmaceuticals in a research report on Wednesday, April 9th. Morgan Stanley lowered their price objective on Alnylam Pharmaceuticals from $284.00 to $268.00 and set an "equal weight" rating on the stock in a research report on Friday, April 11th. Wells Fargo & Company boosted their price objective on Alnylam Pharmaceuticals from $275.00 to $287.00 and gave the company an "equal weight" rating in a research note on Friday, March 21st. Redburn Atlantic assumed coverage on shares of Alnylam Pharmaceuticals in a research note on Monday, March 31st. They set a "buy" rating and a $353.00 target price on the stock. Finally, UBS Group lifted their price target on shares of Alnylam Pharmaceuticals from $331.00 to $349.00 and gave the company a "buy" rating in a report on Friday, May 2nd. One investment analyst has rated the stock with a sell rating, four have given a hold rating and twenty-two have assigned a buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $319.17.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.